Adult Dosing
Acute Lymphoblastic Leukemia
- Recommended dose is 2500 IU/m2 IM/IV q14 days
Notes:- If given IM, do not inject >2 mL at a single injection site. Use only one dose per vial; discard unused product
- If given IV, dilute with 100 mL NaCl or 5% dextrose solution and infuse over 1-2 hrs. After the solution is diluted, use it immediately; may be stored refrigerated at 2°C-8°C for not >48 hrs
Pediatric Dosing
Acute Lymphoblastic Leukemia
- Recommended dose is 2500 IU/m2 IM/IV q14 days
Notes:- If given IM, do not inject >2 mL at a single injection site. Use only one dose per vial; discard unused product
- If given IV, dilute with 100 mL NaCl or 5% dextrose solution and infuse over 1-2 hrs. After the solution is diluted, use it immediately; may be stored refrigerated at 2°C-8°C for not >48 hrs
[Outline]
See Supplemental Patient Information
- Treatment with pegaspargase may lead to serious allergic reactions such as anaphylaxis, especially in patients with known hypersensitivity to other forms of L-asparaginase. Monitor patients for 1 hr following administration, keeping necessary medical equipment and other agents available for management of anaphylaxis
- Serious thrombotic events, including sagittal sinus thrombosis, have been reported during treatment with pegaspargase. If serious thrombotic events occur, discontinue therapy
- Pancreatitis has been reported in patients treated with pegaspargase. If patients complain of abdominal pain, investigate for presence of pancreatitis and discontinue therapy if pancreatitis is confirmed
- Pegaspargase may cause glucose intolerance, which may be irreversible in certain cases
- Increased prothrombin time, increased partial thromboplastin time, and hypofibrinogenemia may occur with pegaspargase use. Monitor coagulation parameters at baseline and regularly during and after therapy. If severe or symptomatic coagulopathy is observed, administer fresh-frozen plasma
Caution: Use cautiously in
- Patients with prior exposure to L-asparaginase
Supplemental Patient Information
- Advise patients to promptly report their physicians if they experience any swellings or difficulty breathing, severe headache, chest pain, severe abdominal pain, excessive thirst or any increase in the frequency or volume of urination
Pregnancy Category:C
Breastfeeding: Safety unknown. Because of a possibility for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, analyzing the importance of the drug to the mother.
